X-VIVO® 15 Serum-free Hematopoietic Cell Medium
X-VIVO® 15 Serum-free Hematopoietic Cell Medium
X-VIVO® 15, Serum-free hematopoietic cell medium, with L-Glutamine, gentamicin and phenol red, xenofree, 500mL
Want to request a quote or find our more information about this product including customization options? Please fill in your request and your local sales specialist will contact you.
Product Overview
X-VIVO® 15 Media are similar in composition to X-VIVO® 10 Media and have been optimized for the proliferation of tumor infiltrating lymphocytes (TIL) under serum-free conditions. X-VIVO® 15 Media support the proliferation of purified CD3+ cells isolated from peripheral blood and human tumors. X-VIVO® 15 Media can also be used to support the growth of human monocytes, macrophage cells and cell lines, PBL, granulocytes, and natural killer (NK) cells. In addition, X-VIVO® 15 Media provide a serum-free environment for the expansion of HUT-78 and related human lymphocytic cell lines.
X-VIVO® 15, catalog number 02-060F and 02-060Q are formulated with L-glutamine, gentamicin, and phenol red. Catalog number 02-053Q is formulated with L-glutamine, gentamicin, recombinant transferrin, and phenol red. The recombinant transferrin replaces native transferrin.
In Americas we offer part 04-418Q.
THIS PRODUCT IS NOT FOR USE IN GMP MANUFACTURING, NOR HUMAN OR ANIMAL IN VIVO USE, INCLUDING USE AS A DILUENT OR AS AN EXCIPIENT, OR FOR DIAGNOSTIC USE. This product is for research use only. If you require GMP grade media, contact Lonza for more details.
Request More InfoApplications
- Proliferation of peripheral blood lymphocytes
- Proliferation of tumor infiltrating lymphocytes
- Cryopreservation of human tissue
- Cultivation of human monocytes and macrophages
- Cultivation of stem cells
- Cultivation of dendritic cells
Storage and Content
500mL bottleSDS, CoA, and Instructions
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
